Physician profile
Ryan A Klitgaard
NPI 1801240809
$4,582.95
in general payments reported to CMS, 2019-2025
48 companies · $802 in 2025
The $802 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $109 · 2021: $287 · 2022: $1,011 · 2023: $784 · 2024: $1,434 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.32 | 2021-2025 | |
| Novo Nordisk INC | $493.41 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $358.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $333.00 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $301.39 | 2019-2025 | |
| Lilly USA, LLC | $271.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Supernus Pharmaceuticals, INC. | $197.70 | 2022-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $196.02 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $156.64 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $141.34 | 2019-2022 | |
| Exact Sciences Corporation | $123.65 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $112.30 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.76 | 2022-2024 | Jardiance |
| Genentech USA, INC. | $84.58 | 2019-2022 | |
| Amgen INC. | $82.85 | 2023-2025 | Repatha, Otezla, Repatha |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Klitgaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.